Machine Learning for analysis of Multiple Sclerosis cross-tissue bulk and single-cell transcriptomics data

Francesco Massafra; Samuele Punzo; Silvia Giulia Galfré; Alessandro Maglione; Simone Pernice; Stefano Forti; Simona Rolla; Marco Beccuti; Marinella Clerico; Corrado Priami; Alina Sîrbu

arXiv · 2603.05572

Machine Learning for analysis of Multiple Sclerosis cross-tissue bulk and single-cell transcriptomics data

Francesco Massafra·Samuele Punzo·Silvia Giulia Galfré·Alessandro Maglione·Simone Pernice·Stefano Forti·Simona Rolla·Marco Beccuti·Marinella Clerico·Corrado Priami·Alina Sîrbu

View original source ↗Read source document ↗Export metadata ↓

Abstract

Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system whose molecular mechanisms remain incompletely understood. In this study, we developed an end-to-end machine learning pipeline to analyze transcriptomic data from peripheral blood mononuclear cells and cerebrospinal fluid, integrating both bulk microarray and single-cell RNA sequencing datasets (concentrating on CD4+ and B-cells). After rigorous preprocessing, batch correction, and gene declustering, XGBoost classifiers were trained to distinguish MS patients from healthy controls. Explainable AI tools, namely SHapley Additive exPlanations (SHAP), were employed to identify key genes driving classification, and results were compared with Differential Expression Analysis (DEA). SHAP-prioritized genes were further investigated through interaction networks and pathway enrichment analyses. The models achieved strong performance, particularly in CSF B-cells (AUC=0.94) and microarray (AUC=0.86). SHAP gene selection proved to be complementary to classical DEA. Gene clusters identified across multiple datasets highlighted immune activation, non-canonical immune checkpoints (ITK, CLEC2D, KLRG1, CEACAM1), ribosomal and translational programs, ubiquitin-proteasome regulation, lipid trafficking, and Epstein-Barr virus-related pathways. Our integrative and explainable framework reveals complementary insights beyond conventional analysis and provides novel mechanistic hypotheses and potential biomarkers for MS pathogenesis.

Explore related subjects

q-bio.GN cs.LG

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Francesco Massafra, Samuele Punzo, Silvia Giulia Galfré, Alessandro Maglione, Simone Pernice, Stefano Forti, Simona Rolla, Marco Beccuti, Marinella Clerico, Corrado Priami, Alina Sîrbu. 2026-03-05. Machine Learning for analysis of Multiple Sclerosis cross-tissue bulk and single-cell transcriptomics data. https://arxiv.org/abs/2603.05572

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

Revolutionizing Genomics with Reinforcement Learning Techniques

In recent years, Reinforcement Learning (RL) has emerged as a powerful tool for solving a wide range of problems, including decision-making and genomics. The exponential growth of raw genomic data over the past two decades has exceeded the capacity of manual analysis, leading to a growing interest in automatic data analysis and processing. RL algorithms are capable of learning from experience with minimal human supervision, making them well-suited for genomic data analysis and interpretation. One of the key benefits of using RL is the reduced cost associated with collecting labeled training data, which is required for supervised learning. While there have been numerous studies examining the applications of Machine Learning (ML) in genomics, this survey focuses exclusively on the use of RL in various genomics research fields, including gene regulatory networks (GRNs), genome assembly, and sequence alignment. We present a comprehensive technical overview of existing studies on the application of RL in genomics, highlighting the strengths and limitations of these approaches. We then discuss potential research directions that are worthy of future exploration, including the development of more sophisticated reward functions as RL heavily depends on the accuracy of the reward function, the integration of RL with other machine learning techniques, and the application of RL to new and emerging areas in genomics research. Finally, we present our findings and conclude by summarizing the current state of the field and the future outlook for RL in genomics.

q-bio.GN↗

arXiv2026

Transcriptomic Models for Immunotherapy Response Prediction Show Limited Cross-cohort Generalisability

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy; yet substantial proportion of patients exhibit intrinsic or acquired resistance, making accurate pre-treatment response prediction a critical unmet need. Transcriptomics-based biomarkers derived from bulk and single-cell RNA sequencing (scRNA-seq) offer a promising avenue for capturing tumour-immune interactions, yet the cross-cohort generalisability of existing prediction models remains unclear.We systematically benchmark nine state-of-the-art transcriptomic ICI response predictors, five bulk RNA-seq-based models (COMPASS, IRNet, NetBio, IKCScore, and TNBC-ICI) and four scRNA-seq-based models (PRECISE, DeepGeneX, Tres and scCURE), using publicly available independent datasets unseen during model development. Overall, predictive performance was modest: bulk RNA-seq models performed at or near chance level across most cohorts, while scRNA-seq models showed only marginal improvements. Pathway-level analyses revealed sparse and inconsistent biomarker signals across models. Although scRNA-seq-based predictors converged on immune-related programs such as allograft rejection, bulk RNA-seq-based models exhibited little reproducible overlap. PRECISE and NetBio identified the most coherent immune-related themes, whereas IRNet predominantly captured metabolic pathways weakly aligned with ICI biology. Together, these findings demonstrate the limited cross-cohort robustness and biological consistency of current transcriptomic ICI prediction models, underscoring the need for improved domain adaptation, standardised preprocessing, and biologically grounded model design.

q-bio.GN↗

arXiv2026

Large Language Model Agents for Evidence Based Genetic Disease Severity Classification

Disease severity classification for genetic conditions is subjective and labor-intensive, creating bottlenecks in genomic screening, where commercial panels vary widely in size and overlap. We developed an autonomous AI agent integrating Reasoning and Acting (ReAct) with Retrieval-Augmented Generation (RAG) to classify 10,211 Human Phenotype Ontology terms. It uses American College of Medical Genetics (ACMG)-endorsed severity guidelines and American College of Obstetricians and Gynecologists (ACOG) quality-of-life criteria to retrieve PubMed literature, generate interpretable reasoning chains, and independently verify claims. At the phenotype level, using expert-curated cohorts, the agent achieved 93.55% accuracy (MCC 0.9237) with 82.6% to 91.4% of claims supported by direct evidence or valid inferences. Gene-level severity was aggregated across 8,738 pairs, identifying 3,283 autosomal recessive pairs with severe or profound presentations. External validation showed 95.2% concordance with Mackenzie's Mission gene list. This system enables standardized panel design by providing reliable, automated classification supported by direct evidence.

q-bio.GN↗